AV Fistulas — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive coding, clinical, and documentation guidance for arteriovenous (AV) fistulas and grafts used for hemodialysis vascular access. Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 – September 30, 2026) and incorporates current CPT 2026 procedure coding. For related end-stage renal disease (ESRD) and chronic kidney disease coding, see the companion Renal Failure / CKD / Dialysis CDG. Use this guide to ensure accurate diagnosis assignment, appropriate CDI query triggers, and defensible documentation for AV fistula/graft creation, maintenance, and complication encounters across all care settings.

🔍 1. Definition

An arteriovenous (AV) fistula is a surgically created direct anastomosis between an artery and a vein, bypassing the capillary bed, to provide reliable, high-flow vascular access for hemodialysis. The most common configuration is a wrist (radiocephalic) or elbow (brachiocephalic or brachiobasilic) fistula. Following creation, a maturation period of typically 6–12 weeks is required before the fistula is suitable for cannulation, as described by KDOQI Vascular Access Guidelines.

An arteriovenous graft (AVG) is a vascular access device created by interposing a prosthetic or biological conduit (most commonly expanded polytetrafluoroethylene, ePTFE) between an artery and a vein when the patient's native vessels are unsuitable for direct fistula creation. Grafts may be used earlier (as soon as 2 weeks post-creation) but carry higher rates of thrombosis and infection compared to native fistulas, per NIDDK hemodialysis access guidance.

Scope of this guide: Dialysis-dependent AV fistulas and grafts — creation, maintenance, complications, and interventional management. Separate classifications apply to congenital AV malformations (Q27.33, Q27.34), traumatic/acquired AV fistulas (I77.0), and pulmonary AV fistulas (Q25.72, I28.0), each addressed in the code set section below.

Epidemiology & Clinical Significance

Approximately 560,000 patients in the United States receive maintenance hemodialysis for ESRD. Vascular access complications are a leading cause of hospitalization among dialysis patients, accounting for roughly 25% of all dialysis-related admissions. Native AV fistulas remain the preferred access type per the Fistula First Breakthrough Initiative due to lower infection risk, longer patency, and lower overall cost. Accurate ICD-10-CM and CPT coding of access creation, revision, and complications directly impacts DRG assignment, HCC risk scores, and quality metrics under CMS ESRD Quality Incentive Program (QIP).

🗂️ 2. Alternative Terminology

The following table lists formal and colloquial terminology coders and CDI specialists may encounter in documentation:

🩺 3. Signs & Symptoms

Clinical presentation varies by the phase of fistula/graft management (creation, maturation, maintenance, or complication). Coders should ensure documentation clearly captures the clinical status precipitating the encounter.

Functioning Access (Normal Findings)

• Palpable thrill (continuous vibration over anastomosis)
• Audible bruit on auscultation
• Adequate flow rates (>600 mL/min for fistulas, >800 mL/min for grafts)
• Visible engorgement of superficial veins along fistula segment

Maturation Failure

• Fistula fails to dilate sufficiently 6–8 weeks post-creation
• Inadequate flow (Qa <500 mL/min)
• Failure of vein wall thickening ("arterialization")
• Vessel diameter <6 mm on ultrasound

Thrombosis (T82.858A / T82.868A)

• Absent thrill and bruit — acute loss of access
• Pain, swelling, or erythema over access site
• Inability to achieve adequate dialysis flow rates
• Collapsed or pulseless fistula segment

Steal Syndrome (Dialysis Access Steal Syndrome)

• Hand pain, pallor, paresthesias, or coolness distal to fistula
• Symptoms worsen during dialysis
• Digital ischemia or gangrene in severe cases
• Reduced digital pressure index (<0.6)

Infection (T82.7xxA)

• Erythema, warmth, swelling, purulent discharge at access site
• Fever, bacteremia, sepsis — especially with Staphylococcus aureus
• Graft infections typically more severe and require explantation

Aneurysm / Pseudoaneurysm

• Pulsatile mass or visible bulge over fistula
• Thinning of overlying skin; skin discoloration
• Risk of rupture if skin is compromised
• True aneurysm: all three vessel wall layers involved
• Pseudoaneurysm (I72.x): contained hematoma communicating with vessel lumen — often needle-track related

Stenosis (Outflow / Central)

• Decreased blood flow rates during dialysis (<300 mL/min drop)
• Prolonged bleeding after needle removal
• Elevated venous pressures during dialysis
• Arm edema (central venous stenosis — I87.1)
• Facial/neck swelling (SVC syndrome from central venous occlusion)

🧭 4. Differential Diagnosis

📋 5. Clinical Indicators for Coders/CDI

The following indicators from the medical record should be captured or queried to ensure complete, accurate coding of AV fistula/graft encounters:

🦴 6. Anatomy & Pathophysiology

Relevant Anatomy

Upper extremity vascular access uses the following vessels, as described in StatPearls: Hemodialysis Access:

• Radial artery / cephalic vein (wrist) → Radiocephalic fistula (Brescia-Cimino) — preferred first option
• Brachial artery / cephalic vein (antecubital) → Brachiocephalic fistula — second-line option
• Brachial artery / basilic vein with transposition → Brachiobasilic fistula — requires two-stage procedure; basilic vein superficialized for cannulation
• Forearm veins / radial or ulnar artery → Forearm transposition (36820)
• Prosthetic graft loops (ePTFE) → Usually brachial artery to antecubital vein or axillary vein

Hemodynamic Changes After AVF Creation

When a surgical anastomosis is created between the high-pressure arterial system and the low-pressure venous system, flow is redirected through the fistula. The resulting high-velocity, turbulent flow causes:

• Vein arterialization: The vein wall thickens and dilates due to increased wall shear stress, a process required for successful maturation
• Increased cardiac output: Significant AVFs (especially upper arm) can increase cardiac output by 1–2 L/min, relevant in patients with pre-existing cardiac disease
• Distal ischemia risk: Arterial blood is "stolen" away from the distal extremity, particularly with high-flow fistulas in elderly or diabetic patients with pre-existing peripheral arterial disease

Pathophysiology of Common Complications

• Thrombosis: Most commonly due to outflow stenosis causing progressive flow reduction, hypercoagulable states, hypotension during dialysis, or external compression. Accounts for >80% of access loss events per KDOQI Guidelines.
• Stenosis: Intimal hyperplasia (smooth muscle cell proliferation) at the venous anastomosis is the hallmark lesion of both native fistula and graft dysfunction. Cephalic arch stenosis is particularly common in brachiocephalic fistulas.
• Infection: Bacteremia from AVG infection is predominantly Staphylococcus aureus (including MRSA); native fistula infections are less frequent. Graft infections often require partial or complete graft excision.
• Steal syndrome: Pathologic reversal of distal arterial flow during dialysis; more common with high-flow brachial artery-based access; managed with DRIL procedure (distal revascularization-interval ligation), PAI (proximalization of arterial inflow), or banding.

💊 7. Medication Impact / Treatment

Anemia Management (ESRD-Related)

Patients with ESRD on hemodialysis require ongoing anemia management. The following agents are relevant to coding and HCPCS billing:

• Erythropoiesis-stimulating agents (ESAs): Epoetin alfa (Q4081 — 100 units for ESRD on dialysis), darbepoetin alfa (J0882), methoxy polyethylene glycol-epoetin beta (J0887). ESA dosing and administration is closely tied to hemoglobin targets per CMS ESRD QIP quality measures.
• IV Iron supplementation: Ferric carboxymaltose (J1439), ferric pyrophosphate citrate (J1443–J1444) — commonly used in dialysis patients for iron-deficiency anemia associated with ESRD.

Anticoagulation / Antiplatelet Therapy

• Antiplatelet agents (aspirin, clopidogrel) may be prescribed to maintain fistula patency, particularly for grafts or recurrent thrombosis
• Warfarin or direct oral anticoagulants (DOACs) used for hypercoagulable states or concurrent atrial fibrillation
• Heparin administered during dialysis sessions for circuit anticoagulation — documented on dialysis flow sheets

Thrombolytic Therapy

• Alteplase (tPA) or other thrombolytics may be administered pharmacomechanically during catheter-directed thrombolysis for AVF/AVG thrombosis (captured under CPT 36904–36906 pharmacomechanical thrombolysis)

Antimicrobial Therapy

• IV vancomycin or daptomycin for MRSA/gram-positive bacteremia from infected graft
• Antibiotic-impregnated grafts or local antibiotic depot therapy for graft salvage in selected cases
• Prolonged IV antibiotics required for graft infection — impacts admission length and DRG assignment

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides